Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156931 | 1.00 | NOS2 (0.47) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL6274592 | 1.00 | NOS2 (0.47) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL29596215 | 0.89 | NOS3 (0.40) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL17434420 | 0.85 | NOS3 (0.53) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL9423322 | 0.85 | NOS3 (0.53) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL8892097 | 0.85 | NOS3 (0.53) | NOS2NOS3NOS1SLC1A1GSR | |
| Hydrochloric Acid SCHEMBL8893490 | 0.82 | NOS3 (0.52) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL12028657 | 0.82 | NOS2 (0.53) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL13857278 | 0.82 | NOS2 (0.53) | NOS2NOS3NOS1SLC1A1GSR | |
| SCHEMBL17669888 | 0.79 | KIF11 (0.36) | NOS2NOS3NOS1SLC1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933642-B1 | SALT ENHANCING COMPOUNDS AND USE | HOFMANN THOMAS FRANK (DE) | 2011-12-21 | — | — | EP | claimed |
| US-20090155440-A1 | Salt Enhancing Compounds and Use | GIVAUDAN SA (CH) | 2009-06-18 | — | — | US | claimed |
| EP-1933642-A1 | SALT ENHANCING COMPOUNDS AND USE | Thomas Frank Hofmann & Andreas Dunkel Inst. für Lebensmittelchemie (DE) | 2008-06-25 | — | — | EP | claimed |
| WO-2007042274-A1 | SALT ENHANCING COMPOUNDS AND USE | THOMAS FRANK HOFMANN & ANDREAS DUNKEL (DE) | 2007-04-19 | — | — | WO | claimed |
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | FIRMENICH INCORPORATED (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2017075257-A2 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-04-06 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| EP-1933642-B1 | SALT ENHANCING COMPOUNDS AND USE | HOFMANN THOMAS FRANK (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20090155440-A1 | Salt Enhancing Compounds and Use | GIVAUDAN SA (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1933642-A1 | SALT ENHANCING COMPOUNDS AND USE | Thomas Frank Hofmann & Andreas Dunkel Inst. für Lebensmittelchemie (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042274-A1 | SALT ENHANCING COMPOUNDS AND USE | THOMAS FRANK HOFMANN & ANDREAS DUNKEL (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | NOS2 1343/4885NOS3 1833/4885NOS1 1201/4885 |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | NOS2 2989/4885NOS3 2192/4885NOS1 3370/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | NOS2 3579/4885NOS3 2469/4885NOS1 2683/4885 |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | NOS2 2989/4885NOS3 2192/4885NOS1 3370/4885 |
| US-20090155440-A1 | Salt Enhancing Compounds and Use | TAS1R1, TAS2R41, TAS2R40 | NOS2 1085/4885NOS3 886/4885NOS1 610/4885 |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | TAS2R50, TAS2R30, TAS2R60 | NOS2 2989/4885NOS3 2192/4885NOS1 3370/4885 |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | TAS2R50, TAS2R30, TAS2R60 | NOS2 2989/4885NOS3 2192/4885NOS1 3370/4885 |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | TRPA1, PDE6G, PDE6D | NOS2 1302/4885NOS3 1169/4885NOS1 743/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | NOS2 1343/4885NOS3 1833/4885NOS1 1201/4885 |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | NOS2 4367/4885NOS3 4130/4885NOS1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.